207_Combined course Presentations

FolFox vs 5FU/CDDP

Phase III trial 267 pts – SCC: 85.8% - Stage III-IV: 61%

FolFOx RT 5FU/CDDP/RT

Grade ¾ toxicities (%) 3-yr PFS (%)

30.6

31.3

18.2 20.2

17.4 17.5

OS (%)

No difference – better tolerated?

Conroy, T., Lancet Oncol. 2014 Mar;15(3):305-14